{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-inflammation", "Arglabin", "Artemisia", "Asteraceae", "COVID-19", "Corona virus"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34655016", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "30"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "15"}], "Language": ["eng"], "ELocationID": ["10.1007/s11033-021-06827-7"], "Journal": {"ISSN": "1573-4978", "JournalIssue": {"Volume": "48", "Issue": "12", "PubDate": {"Year": "2021", "Month": "Dec"}}, "Title": "Molecular biology reports", "ISOAbbreviation": "Mol Biol Rep"}, "ArticleTitle": "Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19.", "Pagination": {"StartPage": "8221", "EndPage": "8225", "MedlinePgn": "8221-8225"}, "Abstract": {"AbstractText": ["Arglabin (l(R),10(S)-epoxy-5(S),5(S),7(S)-guaia-3(4),ll(13)-dien-6,12-olide), is a natural sesquiterpene \u03b3-lactone which was first isolated from Artemisia glabella. The compound has been shown to possess anti-inflammatory activity through inhibition of the NLR Family pyrin domain-containing 3 (NLRP3) inflammasome and production of proinflammatory cytokines including interleukin (IL)-1\u03b2 and IL-18. A more hydrophilic derivative of the compound also exhibited antitumor activity in the breast, colon, ovarian, and lung cancer. Some other synthetic derivatives of the compound have also been synthesized with antitumor, cytotoxic, antibacterial, and antifungal activities. Since both NLRP3 inflammasome and cytokine storm are associated with the pathogenesis of COVID-19 and its lethality, compounds like arglabin might have therapeutic potential to attenuate the inflammasome-induced acute respiratory distress syndrome and/or the cytokine storm associated with COVID-19."], "CopyrightInformation": "\u00a9 2021. Crown."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Manayi", "ForeName": "Azadeh", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran."}], "LastName": "Nabavi", "ForeName": "Seyed Mohammad", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Iranian Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Khayatkashani", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy Research Laboratories and Herbal Analysis Services, University of Greenwich, Central Avenue, Chatham-Maritime, UK."}], "LastName": "Habtemariam", "ForeName": "Solomon", "Initials": "S"}, {"Identifier": ["0000-0003-3711-6763"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Madani Street, Tehran, Iran."}], "LastName": "Khayat Kashani", "ForeName": "Hamid Reza", "Initials": "HR"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Mol Biol Rep", "NlmUniqueID": "0403234", "ISSNLinking": "0301-4851"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Inflammasomes"}, {"RegistryNumber": "0", "NameOfSubstance": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"RegistryNumber": "0", "NameOfSubstance": "Sesquiterpenes, Guaiane"}, {"RegistryNumber": "84692-91-1", "NameOfSubstance": "arglabin"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Artemisia"}, {"QualifierName": ["metabolism"], "DescriptorName": "COVID-19"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Cytokine Release Syndrome"}, {"QualifierName": [], "DescriptorName": "Cytokines"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects"], "DescriptorName": "Inflammasomes"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"QualifierName": [], "DescriptorName": "Pandemics"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Respiratory Distress Syndrome"}, {"QualifierName": ["drug effects", "pathogenicity"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": ["chemistry", "metabolism", "therapeutic use"], "DescriptorName": "Sesquiterpenes, Guaiane"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sohrabi C, Alsafi Z, O\u2019Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) Int J Surg. 2020;76:71\u201376. doi: 10.1016/j.ijsu.2020.02.034.", "ArticleIdList": ["10.1016/j.ijsu.2020.02.034", "PMC7105032", "32112977"]}, {"Citation": "Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12:e7423.", "ArticleIdList": ["PMC7182166", "32337143"]}, {"Citation": "Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606.", "ArticleIdList": ["10.1136/bmj.m606", "PMC7224340", "32075786"]}, {"Citation": "Saeidnia S, Manayi A, Gohari AR, Abdollahi M. The story of beta-sitosterol-a review. Eur J Med Plants. 2014;4:590\u2013609. doi: 10.9734/EJMP/2014/7764.", "ArticleIdList": ["10.9734/EJMP/2014/7764"]}, {"Citation": "Saeidnia S, Asili J, Manayi A, et al. Bioactive sesquiterpene lactone from Artemisia santolina. Bolet\u00edn Latinoamericano y del Caribe de Plantas Medicinales y Arom\u00e1ticas. 2017;16:570\u2013577."}, {"Citation": "Kapepula PM, Kabengele JK, Kingombe M, et al. Artemisia spp. derivatives for COVID-19 treatment: anecdotal use, political hype, treatment potential, challenges, and road map to randomized clinical trials. Am J Trop Med Hyg. 2020;103:960\u2013964. doi: 10.4269/ajtmh.20-0820.", "ArticleIdList": ["10.4269/ajtmh.20-0820", "PMC7470522", "32705976"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629\u2013661. doi: 10.1021/acs.jnatprod.5b01055.", "ArticleIdList": ["10.1021/acs.jnatprod.5b01055", "26852623"]}, {"Citation": "Liu C-x. Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection. Chin Herb Med. 2020;12:97\u2013103. doi: 10.1016/j.chmed.2020.03.004.", "ArticleIdList": ["10.1016/j.chmed.2020.03.004", "PMC7270776", "32518555"]}, {"Citation": "Ren J-l, Zhang A-H, Wang X-J. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. 2020;155:104743. doi: 10.1016/j.phrs.2020.104743.", "ArticleIdList": ["10.1016/j.phrs.2020.104743", "PMC7128263", "32145402"]}, {"Citation": "Mozaffarian V. A dictionary of Iranian plant names, Farhang Moaser. Tehran: Iran; 1996. pp. 542\u2013544."}, {"Citation": "Cheong DH, Tan WD, Wong WF, Tran T. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases. Pharmacol Res. 2020;158:104901. doi: 10.1016/j.phrs.2020.104901.", "ArticleIdList": ["10.1016/j.phrs.2020.104901", "PMC7217791", "32405226"]}, {"Citation": "Orege JI, Adeyemi SB, Tiamiyu BB, Akinyemi TO, Ibrahim YA, Orege OB. Artemisia and Artemisia-based products for COVID-19 management: current state and future perspective. Adv Tradit Med. 2021 doi: 10.1007/s13596-021-00576-5.", "ArticleIdList": ["10.1007/s13596-021-00576-5"]}, {"Citation": "Ivanescu B, Miron A, Corciova A. Sesquiterpene lactones from Artemisia genus: biological activities and methods of analysis. J Anal Methods Chem. 2015 doi: 10.1155/2015/247685.", "ArticleIdList": ["10.1155/2015/247685", "PMC4606394", "26495156"]}, {"Citation": "Lone SH, Bhat KA, Khuroo MA. Arglabin: from isolation to antitumor evaluation. Chemico-Biol Interact. 2015;240:180\u2013198. doi: 10.1016/j.cbi.2015.08.015.", "ArticleIdList": ["10.1016/j.cbi.2015.08.015", "26327249"]}, {"Citation": "Shaikenov T, Adekenov S, Belyaev N, Zakiryanova G. Arglabin. Its structure properties and usage. Portsmouth: Economy Printing; 1997. Mechanism of action of the sesquiterpene from Artemisia glabella \u2018arglabin\u2019in transformed tumor cells; pp. 21\u201331."}, {"Citation": "Bottex-Gauthier C, Vidal D, Picot F, Potier P, Menichini F, Appendino G. In vitro biological activities of arglabin, a sesquiterpene lactone from the Chinese herb Artemisia myriantha Wall. (Asteraceae) Biotechnol Ther. 1993;4:77\u201398.", "ArticleIdList": ["8374514"]}, {"Citation": "Adekenov SM, Mukhametzhanov MN, Kagarlitskii AD, Kupriyanov AN. Arglabin\u2014a new sesquiterpene lactone from Artemisia glabella. Chem Nat Compd. 1982;18:623\u2013624. doi: 10.1007/BF00575063.", "ArticleIdList": ["10.1007/BF00575063"]}, {"Citation": "Adekenov S, Zhabayeva \u0410, Baisarov G. Water-soluble substances of arglabin. Eurasian Chem Technol J. 2020;22:205\u2013211. doi: 10.18321/ectj971.", "ArticleIdList": ["10.18321/ectj971"]}, {"Citation": "Adekenov S. Chemical modification of arglabin and biological activity of its new derivatives. Fitoterapia. 2016;110:196\u2013205. doi: 10.1016/j.fitote.2015.11.018.", "ArticleIdList": ["10.1016/j.fitote.2015.11.018", "26625839"]}, {"Citation": "Shaikenov TE, Adekenov SM, Williams RM, et al. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase. Oncol Rep. 2001;8:173\u2013182.", "ArticleIdList": ["11115593"]}, {"Citation": "Adekenov S, Zhumakayeva A, Perminov V, Bekmanov B, Rakhimov K. Neoadjuvant therapy with drug arglabin for breast cancer with expression of H-Ras oncoproteins. Asian Pac J Cancer Prev. 2020;21:3441\u20133447. doi: 10.31557/APJCP.2020.21.11.3441.", "ArticleIdList": ["10.31557/APJCP.2020.21.11.3441", "PMC8033125", "33247707"]}, {"Citation": "He W, Lai R, Lin Q, Huang Y, Wang L. Arglabin is a plant sesquiterpene lactone that exerts potent anticancer effects on human oral squamous cancer cells via mitochondrial apoptosis and downregulation of the mTOR/PI3K/Akt signaling pathway to inhibit tumor growth in vivo. J Balk Union Oncol. 2018;23:1679\u20131685.", "ArticleIdList": ["30610794"]}, {"Citation": "Abderrazak A, Couchie D, Mahmood D, et al. 0383: anti-inflammatory and anti-atherogenic effects of the inflammasome NLRP3 inhibitor, arglabin, in ApoE2Ki mice fed a high fat diet. Arch Cardiovasc Dis Suppl. 2014;6:6\u20137."}, {"Citation": "Abil\u2019daeva A, Pak RN, Kulyiasov AT, Adekenov SM. [Anti-inflammatory effect of arglabin and 11,13-dihydro-13-dimethylaminoarglabin hydrochloride] Eksp Klin Farmakol. 2004;67:37\u201339.", "ArticleIdList": ["15079907"]}, {"Citation": "Schepetkin IA, Kirpotina LN, Mitchell PT, et al. The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation. Phytochemistry. 2018;146:36\u201346. doi: 10.1016/j.phytochem.2017.11.010.", "ArticleIdList": ["10.1016/j.phytochem.2017.11.010", "PMC5750123", "29216473"]}, {"Citation": "Abderrazak A, El Hadri K, Bosc E, et al. Inhibition of the inflammasome NLRP3 by arglabin attenuates inflammation, protects pancreatic \u03b2-cells from apoptosis, and prevents type 2 diabetes mellitus development in ApoE2Ki mice on a chronic high-fat diet. J Pharmacol Exp Ther. 2016;357:487\u2013494. doi: 10.1124/jpet.116.232934.", "ArticleIdList": ["10.1124/jpet.116.232934", "27044804"]}, {"Citation": "Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250\u2013256. doi: 10.1002/jmv.26232.", "ArticleIdList": ["10.1002/jmv.26232", "PMC7361342", "32592501"]}, {"Citation": "Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497\u2013506. doi: 10.1016/S0140-6736(20)30183-5.", "ArticleIdList": ["10.1016/S0140-6736(20)30183-5", "PMC7159299", "31986264"]}, {"Citation": "Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci. 2014;111:3799\u20133804. doi: 10.1073/pnas.1400593111.", "ArticleIdList": ["10.1073/pnas.1400593111", "PMC3956176", "24572573"]}, {"Citation": "Sendler M, van den Brandt C, Glaubitz J, et al. NLRP3 inflammasome regulates development of systemic inflammatory response and compensatory anti-inflammatory response syndromes in mice with acute pancreatitis. Gastroenterology. 2020;158:253\u2013269. doi: 10.1053/j.gastro.2019.09.040.", "ArticleIdList": ["10.1053/j.gastro.2019.09.040", "31593700"]}, {"Citation": "Lin L, Xu L, Lv W, et al. An NLRP3 inflammasome-triggered cytokine storm contributes to streptococcal toxic shock-like syndrome (STSLS) PLoS Pathog. 2019;15:e1007795. doi: 10.1371/journal.ppat.1007795.", "ArticleIdList": ["10.1371/journal.ppat.1007795", "PMC6553798", "31170267"]}, {"Citation": "Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355\u2013362. doi: 10.1038/s41577-020-0331-4.", "ArticleIdList": ["10.1038/s41577-020-0331-4", "PMC7201395", "32376901"]}, {"Citation": "Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u2013773. doi: 10.1056/NEJMoa2001017.", "ArticleIdList": ["10.1056/NEJMoa2001017", "PMC7092803", "31978945"]}, {"Citation": "Zhao C, Zhao W. NLRP3 inflammasome\u2014a key player in antiviral responses. Front Immunol. 2020;11:211. doi: 10.3389/fimmu.2020.00211.", "ArticleIdList": ["10.3389/fimmu.2020.00211", "PMC7040071", "32133002"]}, {"Citation": "de Rivero Vaccari JC, Dietrich WD, Keane RW, de Rivero Vaccari JP. The inflammasome in times of COVID-19. Front Immunol. 2020;11:2474. doi: 10.3389/fimmu.2020.583373.", "ArticleIdList": ["10.3389/fimmu.2020.583373", "PMC7580384", "33149733"]}, {"Citation": "Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020;11:1518. doi: 10.3389/fimmu.2020.01518.", "ArticleIdList": ["10.3389/fimmu.2020.01518", "PMC7324760", "32655582"]}, {"Citation": "Saeedi-Boroujeni A, Mahmoudian-Sani M-R, Nashibi R, Houshmandfar S, Tahmaseby Gandomkari S, Khodadadi A. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacol Immunotoxicol. 2021;43:247\u2013258. doi: 10.1080/08923973.2021.1925293.", "ArticleIdList": ["10.1080/08923973.2021.1925293", "PMC8146296", "34015982"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "2"}, {"Year": "2021", "Month": "10", "Day": "8"}, {"Year": "2021", "Month": "10", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "16", "Hour": "6", "Minute": "4"}, {"Year": "2021", "Month": "10", "Day": "15"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34655016", "PMC8519322", "10.1007/s11033-021-06827-7", "10.1007/s11033-021-06827-7"]}}], "PubmedBookArticle": []}